GLP-1 medications (such as Ozempic, Wegovy, and similar prescriptions) are increasingly used for weight loss and blood sugar management. While these medications can be helpful for some, they may raise important concerns for individuals with a current or past eating disorder or disordered eating patterns.
GLP-1s work by suppressing appetite, slowing digestion, and increasing feelings of fullness. In eating disorder recovery, reconnecting with hunger and fullness cues is often a central part of healing. When these signals are chemically muted, it can unintentionally reinforce restrictive eating behaviors or make it harder to trust the body. Some individuals also notice increased focus on weight, control around food, or body image concerns—sometimes resurfacing long after recovery felt stable.
Common side effects such as nausea, early fullness, and digestive discomfort may further complicate consistent and adequate nourishment. Over time, reduced intake can impact energy, mood, concentration, and overall well-being. For some, stopping GLP-1 medications may also lead to rebound hunger or weight changes, which can increase distress and vulnerability to relapse.
Eating disorder recovery often emphasizes flexibility, body respect, and moving away from external control of eating. For individuals with an eating disorder history, GLP-1 medications can sometimes pull people away from these recovery values, even unintentionally.
A Gentle Note of Support
If you have a history of eating concerns and are considering or currently using a GLP-1 medication, you are not alone in navigating these complex decisions. Having support from eating disorder–informed professionals can help you prioritize both your physical health and long-term recovery. Therapy can be a space to explore these choices with care, curiosity, and compassion.
If this topic resonates with you, I invite you to reach out to learn more about working together and receiving support that honors your unique relationship with food and your body.
Research & Clinical Reference
- American Psychiatric Association. (2023). Practice Guideline for the Treatment of Patients with Eating Disorders
- Academy for Eating Disorders (AED). (2023). Position statements on weight-inclusive care and eating disorder risk
- Rubino, F. et al. (2020). Obesity management and appetite regulation: implications of GLP-1 receptor agonists. The Lancet
- Fairburn, C. G. (2008). Cognitive Behavior Therapy and Eating Disorders
- Tribole, E., & Resch, E. (2020). Intuitive Eating (4th ed.)
- Tylka, T. L., & Wood-Barcalow, N. (2015). The Body Appreciation Scale-2. Body Image